Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Liabilities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Total Liabilities readings, the most recent being $675.6 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 14.32% to $675.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $675.6 million, a 14.32% increase, with the full-year FY2025 number at $675.6 million, up 14.32% from a year prior.
  • Total Liabilities hit $675.6 million in Q4 2025 for Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $675.6 million in Q4 2025 to a low of $559.1 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $604.4 million (2022), compared with a mean of $607.3 million.
  • Biggest five-year swings in Total Liabilities: soared 68.28% in 2021 and later dropped 4.33% in 2024.
  • Amicus Therapeutics' Total Liabilities stood at $597.8 million in 2021, then increased by 0.56% to $601.1 million in 2022, then grew by 2.76% to $617.7 million in 2023, then decreased by 4.33% to $591.0 million in 2024, then rose by 14.32% to $675.6 million in 2025.
  • The last three reported values for Total Liabilities were $675.6 million (Q4 2025), $638.4 million (Q3 2025), and $611.0 million (Q2 2025) per Business Quant data.